Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens.

Qian, L; Dong, Y B; Zhao, L L; Zhao, H J; Cui, J W; Wang, N Y

Qian, L; Dong, Y B; Zhao, L L; Zhao, H J; Cui, J W; Wang, N Y.

Affiliation

Qian L; Cancer Center, The First Hospital of Jilin University, Changchun, China.
Dong YB; Cancer Center, The First Hospital of Jilin University, Changchun, China.
Zhao LL; Cancer Center, The First Hospital of Jilin University, Changchun, China.
Zhao HJ; Cancer Center, The First Hospital of Jilin University, Changchun, China.
Cui JW; Cancer Center, The First Hospital of Jilin University, Changchun, China.
Wang NY; Cancer Center, The First Hospital of Jilin University, Changchun, China.

Neoplasma ; 66(2): 301-307, 2019 Mar 05.

Article in En | MEDLINE | ID: mdl-30509107

Subject(s)

Carcinoma, Hepatocellular/drug therapy; Liver Neoplasms/drug therapy; Oxaliplatin/therapeutic use; Carcinoma, Hepatocellular/diagnosis; Disease Progression; Humans; Liver Neoplasms/diagnosis; ROC Curve; Retrospective Studies; Survival Rate; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Oxaliplatin / Liver Neoplasms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Neoplasma Year: 2019 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google